Targeting of MyD88 Homodimerization by Novel Synthetic Inhibitor TJ-M2010-5 in Preventing Colitis-Associated Colorectal Cancer

Conclusions:
Our findings suggest that TLR/MyD88 signaling may be a therapeutic target for CAC intervention and MyD88 inhibitors may be a promising therapeutic modality for treating patients with colitis or CAC.

Source: JNCI - December 28, 2015 Category: Cancer & Oncology Authors: Xie, L., Jiang, F.-C., Zhang, L.-M., He, W.-T., Liu, J.-H., Li, M.-Q., Zhang, X., Xing, S., Guo, H., Zhou, P. Tags: Article Source Type: research